DE60203934D1 - Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonisten - Google Patents
Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonistenInfo
- Publication number
- DE60203934D1 DE60203934D1 DE60203934T DE60203934T DE60203934D1 DE 60203934 D1 DE60203934 D1 DE 60203934D1 DE 60203934 T DE60203934 T DE 60203934T DE 60203934 T DE60203934 T DE 60203934T DE 60203934 D1 DE60203934 D1 DE 60203934D1
- Authority
- DE
- Germany
- Prior art keywords
- adreneer
- adenosine
- beta
- pharmaceutical combination
- receptors agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129270.5A GB0129270D0 (en) | 2001-12-06 | 2001-12-06 | Pharmaceutical combination |
| GB0129270 | 2001-12-06 | ||
| PCT/IB2002/005057 WO2003047598A1 (en) | 2001-12-06 | 2002-11-28 | Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60203934D1 true DE60203934D1 (de) | 2005-06-02 |
| DE60203934T2 DE60203934T2 (de) | 2006-02-23 |
Family
ID=9927164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60203934T Expired - Fee Related DE60203934T2 (de) | 2001-12-06 | 2002-11-28 | Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonisten |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP1455799B1 (de) |
| JP (1) | JP2005513041A (de) |
| KR (1) | KR100685557B1 (de) |
| CN (1) | CN1856314A (de) |
| AP (2) | AP2004003082A0 (de) |
| AR (1) | AR037634A1 (de) |
| AT (1) | ATE293982T1 (de) |
| AU (1) | AU2002351066B2 (de) |
| BR (1) | BR0214998A (de) |
| CA (1) | CA2469085A1 (de) |
| CO (1) | CO5580752A2 (de) |
| DE (1) | DE60203934T2 (de) |
| DK (1) | DK1455799T3 (de) |
| EA (1) | EA200400639A1 (de) |
| EC (1) | ECSP045132A (de) |
| ES (1) | ES2239728T3 (de) |
| GB (1) | GB0129270D0 (de) |
| GT (1) | GT200200258A (de) |
| HN (1) | HN2002000348A (de) |
| HR (1) | HRP20040517A2 (de) |
| HU (1) | HUP0402540A3 (de) |
| IS (1) | IS7280A (de) |
| MA (1) | MA27150A1 (de) |
| MX (1) | MXPA04005506A (de) |
| NO (1) | NO20042839L (de) |
| NZ (1) | NZ533054A (de) |
| OA (1) | OA12738A (de) |
| PA (1) | PA8560701A1 (de) |
| PE (1) | PE20030834A1 (de) |
| PL (1) | PL370739A1 (de) |
| PT (1) | PT1455799E (de) |
| SV (1) | SV2004001426A (de) |
| TN (1) | TNSN04101A1 (de) |
| TW (1) | TWI256388B (de) |
| UY (1) | UY27566A1 (de) |
| WO (1) | WO2003047598A1 (de) |
| ZA (1) | ZA200403966B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785969B1 (ko) * | 2004-05-12 | 2007-12-14 | 동아제약주식회사 | Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| JP2016518388A (ja) | 2013-04-30 | 2016-06-23 | オティトピック インク． | 乾燥粉末配合および使用方法 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR102507987B1 (ko) | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| JPWO2022050230A1 (de) * | 2020-09-03 | 2022-03-10 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003960D0 (en) * | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| TWI227240B (en) * | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
-
2001
- 2001-12-06 GB GBGB0129270.5A patent/GB0129270D0/en not_active Ceased
-
2002
- 2002-11-28 HR HR20040517A patent/HRP20040517A2/hr not_active Application Discontinuation
- 2002-11-28 ES ES02785778T patent/ES2239728T3/es not_active Expired - Lifetime
- 2002-11-28 CN CNA028244168A patent/CN1856314A/zh active Pending
- 2002-11-28 NZ NZ533054A patent/NZ533054A/en unknown
- 2002-11-28 PL PL02370739A patent/PL370739A1/xx not_active Application Discontinuation
- 2002-11-28 AP APAP/P/2004/003082A patent/AP2004003082A0/en unknown
- 2002-11-28 BR BR0214998-2A patent/BR0214998A/pt not_active IP Right Cessation
- 2002-11-28 AP APAP/P/2004/003053A patent/AP2004003053A0/en unknown
- 2002-11-28 WO PCT/IB2002/005057 patent/WO2003047598A1/en not_active Ceased
- 2002-11-28 DK DK02785778T patent/DK1455799T3/da active
- 2002-11-28 KR KR1020047008609A patent/KR100685557B1/ko not_active Expired - Fee Related
- 2002-11-28 EP EP02785778A patent/EP1455799B1/de not_active Expired - Lifetime
- 2002-11-28 CA CA002469085A patent/CA2469085A1/en not_active Abandoned
- 2002-11-28 AU AU2002351066A patent/AU2002351066B2/en not_active Ceased
- 2002-11-28 OA OA1200400164A patent/OA12738A/en unknown
- 2002-11-28 EA EA200400639A patent/EA200400639A1/ru unknown
- 2002-11-28 PT PT02785778T patent/PT1455799E/pt unknown
- 2002-11-28 AT AT02785778T patent/ATE293982T1/de not_active IP Right Cessation
- 2002-11-28 HU HU0402540A patent/HUP0402540A3/hu unknown
- 2002-11-28 JP JP2003548853A patent/JP2005513041A/ja active Pending
- 2002-11-28 MX MXPA04005506A patent/MXPA04005506A/es active IP Right Grant
- 2002-11-28 DE DE60203934T patent/DE60203934T2/de not_active Expired - Fee Related
- 2002-11-29 TW TW091134818A patent/TWI256388B/zh not_active IP Right Cessation
- 2002-12-03 PE PE2002001164A patent/PE20030834A1/es not_active Application Discontinuation
- 2002-12-03 HN HN2002000348A patent/HN2002000348A/es unknown
- 2002-12-04 AR ARP020104685A patent/AR037634A1/es unknown
- 2002-12-05 SV SV2002001426A patent/SV2004001426A/es not_active Application Discontinuation
- 2002-12-05 UY UY27566A patent/UY27566A1/es not_active Application Discontinuation
- 2002-12-05 GT GT200200258A patent/GT200200258A/es unknown
- 2002-12-06 PA PA20028560701A patent/PA8560701A1/es unknown
-
2004
- 2004-05-21 ZA ZA200403966A patent/ZA200403966B/xx unknown
- 2004-05-21 IS IS7280A patent/IS7280A/is unknown
- 2004-06-02 MA MA27710A patent/MA27150A1/fr unknown
- 2004-06-03 CO CO04052108A patent/CO5580752A2/es not_active Application Discontinuation
- 2004-06-04 TN TNP2004000101A patent/TNSN04101A1/fr unknown
- 2004-06-04 EC EC2004005132A patent/ECSP045132A/es unknown
- 2004-07-05 NO NO20042839A patent/NO20042839L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60201988D1 (de) | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat | |
| ATE307571T1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
| CY2007013I1 (el) | Νεες συνταγοποιησεις αγωνιστου εξεντινης και μεθοδοι χορηγησης αυτων | |
| ATE345133T1 (de) | Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin | |
| DE60201859D1 (de) | Pharmazeutische Verwendung von N-Carbamoylazol-Derivate | |
| NO20033384L (no) | Farmasoytisk formulering | |
| DE60213592D1 (de) | Flüssige pharmazeutische zusammensetzung | |
| DE60208159D1 (de) | Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden | |
| EE200300311A (et) | Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| DE60329755D1 (de) | Basische nichtpeptid-bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus | |
| ATE383868T1 (de) | Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka | |
| ITMI20011057A0 (it) | Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi | |
| ATE350016T1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
| DE60203934D1 (de) | Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonisten | |
| DE60017465D1 (de) | Kombination aus fluazuron und ivermectin gegen parasiten | |
| EE200300454A (et) | Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine | |
| PT1448566E (pt) | Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo | |
| DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
| DE60214533D1 (de) | Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen | |
| ATE350029T1 (de) | Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain | |
| DE60235139D1 (de) | Recheneinheit und Empfangseinheit | |
| EE200200435A (et) | Selektiivsed alfa-2B-adrenotseptori antagonistid ja nende kasutamine | |
| NO20041236L (no) | Farmasoytisk formulering | |
| SE9904414D0 (sv) | Pharmaceutical composition and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |